# New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

- Source: PR Newswire
- Published: 2026-10-25T07:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/new-data-on-lillys-investigational-treatment-olomorasib-at-esmo-2026-show-durable-first-line-activity-in-kras-g12c-mutant-non-small-cell-lung-cancer-302918479.html
- Canonical: https://groundlevelnews.com/story/new-data-on-lilly-s-investigational-treatment-olomorasib-at-esmo-2026--44c025/

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) across PD-L1 expression levels First-line treatment options...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._